Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Digital technologies for medicines: shaping a framework for success

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 19, 573-574 (2020)



The authors acknowledge the contributions to this article of the following experts: C. Vincenzi (EMA); S. Corriol-Rohou (AstraZeneca); F. Albissola (Sanofi); S. Almeida (Medicines for Europe); M. vonFritschen (Eucope); A. Schepers (GSK), F. Ruediger (Grunenthal) and T. Chesworth (AstraZeneca).


The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the organizations they are affiliated with, the European Medicines Agency or one of its committees or working parties.

Competing Interests

T.M. is employed by F. Hoffmann-La Roche and owns shares. S.A. is employed by Novartis Pharma and owns shares. J.D. is employed by Alexion and owns shares.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links